On Invalid Date, Exact Sciences (NASDAQ: EXAS) reported Q1 2023 earnings per share (EPS) of -$0.42, up 59.62% year over year. Total Exact Sciences earnings for the quarter were -$74.15 million. In the same quarter last year, Exact Sciences's earnings per share (EPS) was -$1.04.
On Invalid Date, Exact Sciences (NASDAQ: EXAS) reported Q1 2023 revenue of $602.45 million up 23.82% year over year. In the same quarter last year, Exact Sciences's revenue was $486.57 million.
What was EXAS's revenue growth in the past year?
As of Q2 2023, Exact Sciences's revenue has grown 18.83% year over year. This is 12.91 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 5.92%. Exact Sciences's revenue in the past year totalled $2.20 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.